Fig. 7: Sotorasib-resistant KRAS mutated cells remain sensitive to pan-ERBB/AURK inhibition.
From: KRAS mutated lung adenocarcinoma responds to pan-ERBB and Aurora kinase inhibitors
a Exposure to increasing concentrations of sotorasib over time conferred PULM21 cells resistant to the treatment (10 µM). Representative images of crystal violet staining of colonies after ten days are shown (n = 3 per group). ImageJ was used for quantification. Data are presented as mean values ± SEM. *** P < 0.001 (Student’s t test). Sensitive cells are indicated as SS; resistant cells are labeled with SR. b Changes in signaling upon resistance to sotorasib were assessed by immunoblot. HSC70 was used as a loading control. c PULM21-SR cells were treated with vehicle or the indicated drugs (37 nM each compound). Representative images of crystal violet staining of colonies after ten days are shown (n = 3 per group). ImageJ was used for quantification. Error bars indicate ± SEM. **P < 0.01, ****P < 0.0001 (One-way ANOVA with subsequent Bonferroni posttest). d PULM21-SR cells were treated with vehicle or the indicated agents (37 nM each compound) and assessed by immunoblot at 48 hours. HSC70 served as a loading control.
